All
Frontline Immunochemotherapy Recommended in Advanced-Stage Follicular Lymphoma
January 16th 2018Long-term follow-up results of the FOLL05 trial confirm the efficacy of immunochemotherapy regimens for patients with previously untreated advanced-stage follicular lymphoma, according to findings of a post-hoc analysis recently published in the <em>Journal of Clinical Oncology </em>covering a median 7 years of follow-up.
Mark Israel Joins the Israel Cancer Research Fund as National Executive Director
January 16th 2018A nationally recognized leader in cancer research, Mark A. Israel, MD, has joined the Israel Cancer Research Fund as national executive director. The ICRF is the largest nonprofit organization dedicated exclusively to funding cancer research in Israel at present.
The Influence of Mutational Status in Intrahepatic Cholangiocarcinoma
January 15th 2018Jesper B. Andersen, MSc, PhD, discusses a study that shows using a single-gene dissection approach in patients with intrahepatic cholangiocarcinoma can characterize divergent cancer programs and drug vulnerabilities.
Afatinib Approval for Lung Cancer Expanded by FDA
January 15th 2018The frontline indication for afatinib (Gilotrif) has been expanded by the FDA to include the treatment of patients with metastatic non–small cell lung cancer whose tumors harbor uncommon <em>EGFR</em> alterations in L861Q, G719X, and/or S768I.
Landgren Discusses Treatment Options in 2 Cases of Multiple Myeloma
January 15th 2018C. Ola Landgren, MD, PhD, recently shared the treatment considerations and decisions he makes when treating patients with multiple myeloma. Landgren, chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center, in New York, explained his treatment decisions based on 2 case scenarios during a <em>Targeted Oncology</em> live case-based peer perspectives dinner.
New McLeod Prostate Cancer Translational Research Fellowship Presented to Prachi Mishra
January 15th 2018Prachi Mishra, PhD, was awarded the first “Colonel (Ret.) David G. McLeod Prostate Cancer Translational Research Fellowship” at the Uniformed Services University of Health Sciences on December 7. She was presented this award in front of Department of Defense leadership, industry leaders, cancer scientists, military healthcare providers, and other colleagues.
Asian Patients With mCRC See Improved Survival With TAS-102
January 12th 2018According to findings from the phase III TERRA trial published in the <em>Journal of Clinical Oncology, </em>previously treated Asian patients with metastatic colorectal cancer saw a significant survival benefit with TAS-102 (trifluridine and tipiracil; Lonsurf) compared with placebo.
Kulke Appointed Chief of Hematology/Oncology at BUMC
January 12th 2018Boston University Medical Center has announced that Matthew Kulke, MD, will serve as its chief of the Section of Hematology/Oncology in the Department of Medicine, effective March 1, 2018. Kulke will also obtain the roles of deputy director of the BU-BMC Cancer Center, medical director of the Clinical Cancer Center at BMC, and the Zoltan Kohn Professor of Medicine at the Boston University School of Medicine.
Rugo Discusses Long-Term Findings Supporting Nab-Paclitaxel as a Promising Option in First-Line TNBC
January 12th 2018Hope S. Rugo, MD, discusses findings of the CALGB 40502/NCCTG N063H study, which was a randomized phase III trial of paclitaxel compared with nab-paclitaxel or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer.
Hochster Joins Rutgers Cancer Institute of New Jersey and RWJBarnabas Health
January 12th 2018Howard S. Hochster, MD, an internationally recognized leader in the development of cancer clinical trials, gastrointestinal oncology, and early phase cancer drugs, has joined Rutgers Cancer Institute of New Jersey as associate director for clinical research and chief of gastrointestinal medical oncology.
Expert Discusses Impressive Findings With Sacituzumab Govitecan in Metastatic TNBC
January 11th 2018Aditya Bardia, MD, MPH, discusses phase I/II trial of sacituzumab govitecan which showed favorable clinical activity in patients with relapsed or refractory metastatic triple-negative breast cancer who have received at least 2 prior treatment regimens.
Superior PFS Maintained Over Time With Daratumumab in Relapsed/Refractory Myeloma
January 11th 2018According to an updated analysis of the POLLUX trial, progression-free survival remained superior over time in patients with relapsed/refractory multiple myeloma treated with combination therapy that included the anti-CD38 antibody daratumumab.
Letrozole Maintenance Demonstrates Improved RFS in Ovarian Cancer
January 10th 2018According to a small, single-site prospective observation, women with ER-positive advanced high-grade serous ovarian cancer who received maintenance therapy with letrozole were more likely to be recurrence-free at 24 months, suggesting that letrozole may have a role to play in this setting, especially for patients with chemotherapy resistance or residual disease.<br />
Pembrolizumab Receives Approval in Japan for Urothelial Carcinoma
January 9th 2018Pembrolizumab (Keytruda) has been approved in Japan for the treatment of patients with radically unresectable urothelial carcinoma who progressed after cancer chemotherapy, according to Merck, the manufacturer of the PD-1 inhibitor.
Pembrolizumab/Lenvatinib Combo Granted FDA's Breakthrough Therapy Designation for RCC
January 9th 2018Based on results of the Ib/II Study 111, the combination of the PD-1 inhibitor pembrolizumab and the VEGF/FGF inhibitor lenvatinib has been granted a breakthrough therapy designation by the FDA for the treatment of patients with advanced and/or metastatic renal cell carcinoma.
Denosumab Granted FDA Approval for Multiple Myeloma
January 5th 2018Based on data from the phase III 482 study, denosumab (Xgeva) has been granted FDA approval for the prevention of skeletal-related events in patients with multiple myeloma, according to Amgen, the developer of the RANK ligand inhibitor.
Frontline Eltrombopag Receives FDA's Breakthrough Therapy Designation for Severe Aplastic Anemia
January 5th 2018Eltrombopag (Promacta) has been granted a breakthrough therapy designation by the FDA for use in combination with standard immunosuppressive therapy for the first-line treatment of patients with severe aplastic anemia.
The Evolving Role of Targeted Therapies in Melanoma
January 4th 2018Hussein A. Tawbi, MD, discusses the considerations he makes when choosing between immunotherapy and targeted therapy for patients with melanoma and how long-term targeted therapy data can influence treatment decisions.<br />
Expert Discusses Treatment Approaches, Research Needs for Patients With Extracutaneous Melanomas
January 4th 2018Richard D. Carvajal, MD, discusses considerations when diagnosing and treating extracutaneous melanomas and the importance of treating such diseases differently than the more commonly seen melanomas.
A Look Back at FDA News in the Month of December
January 3rd 2018The FDA closed out the year by approving several new agents last month, including bevacizumab for glioblastoma, cabozantinib for renal cell carcinoma, nivolumab for melanoma, bosutinib for chronic myeloid leukemia, and pertuzumab for HER2+ breast cancer. In addition, several agents were granted a priority review designation. Here is a look back at all the FDA activity that took place in December.
Ribociclib Granted Breakthrough Therapy Designation by FDA for HR+/HER2- Premenopausal Breast Cancer
January 3rd 2018Based on results of the phase III MONALEESA-7 trial, ribociclib (Kisqali) has been granted a breakthrough therapy designation by the FDA for use in combination with tamoxifen or an aromatase inhibitor as frontline treatment for pre- or perimenopausal women with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.